Theravance Biopharma
TBPH
135 hedge funds and large institutions have $512M invested in Theravance Biopharma in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 20 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
28% more capital invested
Capital invested by funds: $401M → $512M (+$111M)
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
3% more funds holding
Funds holding: 131 → 135 (+4)
2.12% more ownership
Funds ownership: 90.75% → 92.87% (+2.1%)
99% less call options, than puts
Call options by funds: $3K | Put options by funds: $286K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.69M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.87M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$2.48M |
| 4 |
NM
Newtyn Management
New York
|
+$1.87M |
| 5 |
Morgan Stanley
New York
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$5.35M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.47M |
| 3 |
Millennium Management
New York
|
-$2.41M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.98M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.38M |
TBPH Hedge Fund Activity: Q2 2025 in Review
135 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2025, worth a combined $512M — up 28% from $401M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TBPH positions and 20 closed out — a net gain of 4 holders — while 54 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $6.69M. The largest seller was Camber Capital Management, cutting an estimated $5.35M.
- 135 institutional investors held Theravance Biopharma (TBPH) as of Q2 2025, up from 131 in Q1 2025.
- Funds reported $512M of Theravance Biopharma stock for Q2 2025, up 28% quarter-over-quarter.
- 24 funds opened new Theravance Biopharma positions in Q2 2025 and 20 closed out, a net change of +4 holders.
- The largest Theravance Biopharma buyer in Q2 2025 was BlackRock, an estimated $6.69M added.
- The largest Theravance Biopharma seller in Q2 2025 was Camber Capital Management, an estimated $5.35M sold.
Based on aggregated 13F filings for Q2 2025.